Nutriband Inc
$ 3.98
2.05%
13 Apr - close price
- Market Cap 47,482,000 USD
- Current Price $ 3.98
- High / Low $ 3.99 / 3.81
- Stock P/E N/A
- Book Value 0.62
- EPS -3.05
- Next Earning Report 2026-04-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.36 %
- 52 Week High 11.68
- 52 Week Low 3.42
About
Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.
Analyst Target Price
$15.00
Quarterly Earnings
| Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-10 | 2025-10-01 | 2025-05-02 | 2025-04-28 | 2024-12-10 | 2024-09-03 | 2024-05-01 | 2024-04-30 | 2023-12-13 | 2023-09-11 | 2023-06-09 | 2023-04-26 |
| Reported EPS | -0.32 | -2.12 | -0.5 | -0.51 | -0.1227 | -0.1542 | -0.2072 | -0.2295 | -0.2247 | -0.1059 | -0.1296 | -0.21 |
| Estimated EPS | -2.13 | -0.17 | -0.12 | -0.12 | None | None | None | None | -0.06 | -0.07 | -0.06 | -0.04 |
| Surprise | 1.81 | -1.95 | -0.38 | -0.39 | 0 | 0 | 0 | 0 | -0.1647 | -0.0359 | -0.0696 | -0.17 |
| Surprise Percentage | 84.9765% | -1147.0588% | -316.6667% | -325% | None% | None% | None% | None% | -274.5% | -51.2857% | -116% | -425% |
Next Quarterly Earnings
| Jan 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-01-31 |
| Estimated EPS | -1.89 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTRB
2026-04-07 20:11:11
Nutriband has announced the selection of a global brand name for its abuse-deterrent fentanyl transdermal system and has begun regulatory and trademark submissions. The company's AVERSA technology aims to create a first-in-class abuse-deterrent patch to curb opioid misuse, targeting substantial pain-management markets. This move is a key step towards the commercialization of the product, with estimated annual peak sales in the U.S. alone ranging from $80 million to $200 million.
2026-04-07 20:10:17
Nutriband Inc. (NASDAQ: NTRB) has selected a commercial worldwide brand name for its abuse-deterrent fentanyl transdermal patch, which uses its AVERSA™ technology. The company will submit the name and labeling to regulatory bodies like the FDA and has initiated trademark protection. A market analysis suggests peak annual U.S. sales for the product could reach between $80 million and $200 million.
2026-04-02 14:40:06
Nutriband Inc. (NTRB) reported a Q1 loss, missing revenue estimates. The company's financial performance fell short of analyst expectations for the quarter.
2026-04-01 19:11:46
Nutriband Inc. (NTRB) reported a loss for the first quarter, failing to meet revenue estimates. This indicates a challenging start to the year for the company, as its financial performance fell short of analyst expectations. The report likely details the extent of the loss and the specific revenue figures that contributed to the miss.
2026-04-01 15:11:46
Nutriband (NASDAQ: NTRB) has chosen a global brand name candidate for its AVERSA(TM) abuse-deterrent fentanyl transdermal system. The company plans to submit the name and product labeling to regulatory bodies and seek trademark protection. This product aims to be the first abuse-deterrent fentanyl patch to reduce misuse and accidental exposure, targeting a significant U.S. market and broader global pain management needs.
2026-04-01 14:11:46
Nutriband Inc (NTRB) is currently exhibiting a "Strong Sell" technical sentiment as of April 1, 2026, according to an analysis of 12 technical signals. The stock's current price of $3.6 is below its 20-day, 60-day, and 200-day simple moving averages, contributing to negative momentum indicators like the MACD and Awesome Oscillator. Key support is identified at $3.409 and resistance at $4.069, with the Relative Strength Index (RSI) indicating a neutral condition.
